DBV Technologies | DBVT - Gross Profit On Sales


DBV Technologies reported $2.77M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amarin USD 23.17M 961K Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
DBV Technologies USD 2.77M 33.21M Sep/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Insmed USD 256.46M 38.78M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025